Diana Ernst, RPh

Editorial Director https://www.empr.com

Diana Ernst, RPh, is the Editorial Director for MPR, part of the Haymarket Medical Network. Since 2003, Diana has worked to provide healthcare professionals with up-to-date drug information through MPR's print and digital offerings. She is a graduate of the Ernest Mario School of Pharmacy, Rutgers University.

All articles by Diana Ernst, RPh

COPD

FDA Rejects NDA for Triple Combination COPD Therapy

Diana Ernst, RPh

October 4, 2019

The FDA has issued a CRL to AstraZaeneca regarding their NDA for PT010, an investigational triple combination therapy for COPD.

Pneumonia

Three-Drug Combo Promising in Hospital-Acquired, Ventilator-Associated Bacterial Pneumonia Study

Diana Ernst, RPh

October 3, 2019

Imipenem/relebactam/cilastatin was found to be noninferior to piperacillin/tazobactam in adult patients with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.

Asthma

Real-World Study Shows Mepolizumab Reduces Exacerbations in Severe Eosinophilic Asthma

Diana Ernst, RPh

October 2, 2019

Treatment with mepolizumab was associated with a significant reduction in asthma exacerbations and oral corticosteroid use in patients with severe eosinophilic asthma.

Whole brain radiotherapy does not improve overall survival or quality of life among patients with br

Lung Cancer

Antibiotic Use May Affect Lung Cancer Survival When Treated With Pembrolizumab

Diana Ernst, RPh

September 25, 2019

In patients with naïve advanced NSCLC and high PD-LI expression who are treated with pembrolizumab, the use of IV antibiotics may negatively impact progression free survival and overall survival.

Pneumonia

Ceftaroline Fosamil Now Approved for Acute Bacterial Skin/Skin Structure Infections in Younger Patients

Diana Ernst, RPh

September 23, 2019

The FDA has expanded the indication for Teflaro (ceftaroline fosamil; Allergan) to include treatment of acute bacterial skin and skin structure infections in pediatric patients.

Allergies

FDA Committee Votes on AR101 for Peanut Allergy

Diana Ernst, RPh

September 18, 2019

The FDA’s Allergenic Products Advisory Committee voted in favor of the approval of Palforzia (AR101) as a treatment to reduce the incidence and severity of allergic reactions.